Needlestick From a Hepatitis B-Positive Source: HBIG Now, But Which Vaccine?
A single patient, an hour past a needlestick from a hepatitis B-positive source with no protective antibody of her own. HBIG isn't in question — which vaccine is sitting in the refrigerator tonight is.
C.O., a 26-year-old woman, is in her second semester of nursing school and waits tables three nights a week to cover rent and tuition, a schedule that leaves her running on too little sleep most weeks but determined to finish the program without going further into debt than she already has. Tonight's clinical rotation on the medical floor was supposed to be routine — starting a peripheral IV on a patient with a documented history of chronic hepatitis B — until the patient moved unexpectedly during the stick and the hollow-bore needle went through the side of C.O.'s glove into her thumb. The source patient's chart, pulled within the hour by employee health, showed HBsAg-positive chronic infection with a high viral load on his most recent labs. C.O.'s own vaccination record is incomplete — she started the hepatitis B series in high school and never finished it, and a same-night rapid anti-HBs test came back negative, confirming she has no protective antibody — the one piece of information that turns tonight from a routine exposure workup into an actual post-exposure prophylaxis decision rather than a reassurance conversation.
The post-exposure algorithm for an unvaccinated worker exposed to a known HBsAg-positive source is not in dispute: hepatitis B immune globulin as soon as possible, ideally within twenty-four hours, given alongside the start of the vaccine series at a separate injection site. The 85-to-95-percent figure everyone attaches to that combination is worth reading carefully before it gets applied to her: it comes from perinatal studies, where HBIG at birth plus the vaccine series prevented the carrier state at that rate. The occupational literature is thinner and older — for percutaneous exposure, the regimen actually studied head-to-head was two doses of HBIG, around 75 percent effective — and all of it predates any two-dose vaccine, because three-dose products were the only ones that existed when those studies were run. What's actually being argued in employee health tonight is smaller and more current than the PEP algorithm itself: the vaccine sitting in the refrigerator down the hall is Heplisav-B, a newer two-dose formulation that has shown equal or higher seroconversion rates than the older three-dose vaccines in general adult vaccination studies, but has not itself been directly studied in the specific context of same-night co-administration with HBIG after an acute high-risk exposure — a narrower, real gap in a literature that is otherwise settled.
Employee health, the same night
HBIG works best given fast. Past about seven days we don't have effectiveness data at all — not reassuring data, no data — so "we have a week" is the wrong way to hold it, and I don't want to lose an hour deciding on vaccine brand while that clock runs. What's in the fridge tonight is Heplisav-B. ACIP approves it without restriction for adults her age. I'd give both tonight and move on.
You're right that HBIG shouldn't wait on this conversation — nobody's arguing to hold it. But the eighty-five to ninety-five percent efficacy number everyone quotes for combined HBIG-plus-vaccine PEP comes from studies — the original perinatal-transmission trials and the occupational-exposure literature built on them — that used three-dose vaccines exclusively, because that's all that existed. Heplisav-B has strong general-population immunogenicity data, but nobody has specifically re-run that efficacy number with Heplisav-B substituted into the PEP regimen. That's not evidence it doesn't work here — it's an absence of the specific evidence, and I don't think we should treat those as the same thing.
They're not the same thing, and I'll draw the distinction the other way: Heplisav-B is the same recombinant surface antigen the three-dose vaccines use, with a different adjuvant, and across the randomized immunogenicity trials that supported its approval it produced seroprotection in 90 to 100 percent of adults against Engerix-B's 70 to 90. ACIP reviewed exactly that evidence in February 2018 and recommended it for any adult eighteen or over for whom hepatitis B vaccination is indicated, with no PEP-specific carve-out or caution.
An absence of a dedicated co-administration trial isn't the same as a documented gap in performance — and holding her HBIG, or sending someone driving around at eleven at night looking for a three-dose product, to close a gap that exists only in the literature and not in the biology, is the wrong place to spend the next hour. Give her both tonight, and flag her chart so her antibody response gets confirmed at series completion either way.
Agreed: HBIG and the Heplisav-B series both given the same night, without delaying either to source the older three-dose vaccine.
Also agreed: C.O.'s case will be flagged for anti-HBs confirmation at series completion, so her own antibody response is directly verified rather than assumed — the practical answer to the pharmacist's concern about the co-administration data gap, without requiring a delay tonight.